approves bill for generic biologics
The measure would allow generic producers to apply to the Food and Drug Administration to produce generic biologics that are either “biosimilar,” which means they show no meaningful clinical differences to the original, or “interchangeable,” which means the drug can be substituted for the original without the approval of a physician.
Explore posts in the same categories: Sexual Health